Survival in patients diagnosed with SMA at less than 24 months of age in a population-based setting before, during and after introduction of nusinersen therapy. Experience from Sweden


      • Data on survival from real world is scares. Here we provide data on survival in a population-based setting.
      • We did not see significant difference in survival between the three calendar periods when not separated by treatment status.
      • The introduction of nusinersen has led to significant prolongation of life expectancy in children with SMA in Sweden.



      Clinical trials have demonstrated a positive effect of nusinersen therapy on survival of infants with SMA type 1. However, there is a lack of data outside clinical trials on how the introduction of nusinersen has affected the survival of patients with SMA. We therefore set out to analyse survival in patients diagnosed at less than 24 months before, during and after the introduction of nusinersen in a nationwide population-based real-world setting.


      SMA patients diagnosed before the age of 24 months in the time period between February 21, 2000 and December 19, 2019 were identified using ICD-codes, and medical procedures for identification of treatment utilizing information from the public available National Patient Registry held by the National Board of Health and Welfare. Data was divided into 3 different calendar periods (before, during, and after introduction of nusinersen treatment in Sweden).
      Time to Event analysis was then applied.


      A total of 155 patients were enrolled in the study, and median follow-up was 1.14 years (inter-quartile range (IQR): 0.27–8.37 years). Data did not provide conclusive evidence that survival differed between the calendar periods (P-value from the log-rank test = 0.419) and while hazards were lower in the middle period, HR 0.70 (95% CI: 0.34–1.47), and 3, HR 0.71 (95% CI: 0.28–1.77) compared to the first period, all confidence intervals were wide., However, nusinersen treatment was associated with a decreased mortality rate, HR 0.05 (95% CI: 0.01–0.37).


      SMA patients receiving nusinersen therapy had a dramatically increased overall survival compared to patients not receiving therapy. This indicates that nusinersen treatment has an effect on survival, in patients diagnosed with SMA, in a nationwide real-world setting. Larger studies are warranted.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Paediatric Neurology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Finkel R.
        • Bertini E.
        • Muntoni F.
        • Mercuri E.
        Group ESWS. 209th ENMC international workshop: outcome measures and clinical trial readiness in spinal muscular atrophy 7-9 november 2014, heemskerk, The Netherlands.
        Neuromuscul. Disord. 2015; 25: 593-602
        • Finkel R.S.
        • McDermott M.P.
        • Kaufmann P.
        • Darras B.T.
        • Chung W.K.
        • Sproule D.M.
        • et al.
        Observational study of spinal muscular atrophy type I and implications for clinical trials.
        Neurology. 2014; 83: 810-817
        • Darras B.T.
        Spinal muscular atrophies.
        Pediatr. Clin. 2015; 62: 743-766
        • De Sanctis R.
        • Coratti G.
        • Pasternak A.
        • Montes J.
        • Pane M.
        • Mazzone E.S.
        • et al.
        Developmental milestones in type I spinal muscular atrophy.
        Neuromuscul. Disord. 2016; 26: 754-759
        EUROPEAN medicines agency.
        ([Available from:)
      1. FDA approves first drug for spinal muscular atrophy: U.S.
        Food Drug Adm. 2016; ([Available from:)
        • Finkel R.S.
        • Mercuri E.
        • Darras B.T.
        • Connolly A.M.
        • Kuntz N.L.
        • Kirschner J.
        • et al.
        Nusinersen versus sham control in infantile-onset spinal muscular atrophy.
        N. Engl. J. Med. 2017; 377: 1723-1732
        • Mercuri E.
        • Darras B.T.
        • Chiriboga C.A.
        • Day J.W.
        • Campbell C.
        • Connolly A.M.
        • et al.
        Nusinersen versus sham control in later-onset spinal muscular atrophy.
        N. Engl. J. Med. 2018; 378: 625-635
        • Janusinfo - Spinraza
        ([Available from:)
        • Ludvigsson J.F.
        • Andersson E.
        • Ekbom A.
        • Feychting M.
        • Kim J.L.
        • Reuterwall C.
        • et al.
        External review and validation of the Swedish national inpatient register.
        BMC Publ. Health. 2011; 11: 450
        • Brooke H.L.
        • Talback M.
        • Hornblad J.
        • Johansson L.A.
        • Ludvigsson J.F.
        • Druid H.
        • et al.
        The Swedish cause of death register.
        Eur. J. Epidemiol. 2017; 32: 765-773
        • Putter H.
        • Fiocco M.
        • Geskus R.B.
        Tutorial in biostatistics: competing risks and multi-state models.
        Stat. Med. 2007; 26: 2389-2430
        • R Development Core Team R
        1 ed. A Language and Environment for Statistical Computing. 4.1. R Foundation for Statistical Computing, Vienna, Austria2021
        • Wadman R.I.
        • van der Pol W.L.
        • Bosboom W.M.
        • Asselman F.L.
        • van den Berg L.H.
        • Iannaccone S.T.
        • et al.
        Drug treatment for spinal muscular atrophy types II and III.
        Cochrane Database Syst. Rev. 2020; 1: CD006282